Intercept ' s Drug for Liver Fibrosis Due to NASH Meets Main Goal Intercept ' s Drug for Liver Fibrosis Due to NASH Meets Main Goal

Intercept Pharmaceuticals Inc said on Tuesday its treatment in patients with nonalcoholic steatohepatitis (NASH) showed an improvement in liver fibrosis, taking the drug a step closer to approval.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news